Mind Medicine Inc. (MNMD) has released an update.
Mind Medicine Inc. reports a triumphant year with positive Phase 2b outcomes for their GAD treatment, MM120, and has announced upcoming milestones including a March investor event to discuss new data. The company is also preparing for a Phase 3 clinical program in the latter half of 2024 and has kicked off a Phase 1 trial for a new treatment targeting Autism Spectrum Disorder.
For further insights into MNMD stock, check out TipRanks’ Stock Analysis page.
